Relay Therapeutics: T. Rowe Price reports 8.2% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 17,868,157 Relay Therapeutics, Inc. (RLAY) common shares, or 8.2% of the class. It reported sole voting power over 17,031,683 shares and sole dispositive power over 17,868,157 shares, with no shared voting or dispositive power. The company expressly denied being the beneficial owner and said the disclosure should not be construed as an admission of beneficial ownership.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.